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Abstract
Background: The Swiss COPD cohort was established in 2006 to collect data in a primary care setting. The objective
of this study was to evaluate possible predictive factors for exacerbation and re-exacerbation.
Methods: In order to predict exacerbation until the next visit based on the knowledge of exacerbation since the last
visit, a multistate model described by Therneau and Grambsch was performed.
Results: Data of 1,247 patients (60.4% males, 46.6% current smokers) were analyzed, 268 (21.5%) did not fulfill spirometric
diagnostic criteria for COPD. Data of 748 patients (63% males, 44.1% current smokers) were available for model analysis. In
order to predict exacerbation an extended Cox Model was performed. Mean FEV1/FVC-ratio was 53.1% (±11.5), with a
majority of patients in COPD GOLD classes 2 or 3. Hospitalization for any reason (HR1.7; P = 0.04) and pronounced
dyspnea (HR for mMRC grade four 3.0; P < 0.001) at most recent visit as well as prescription of short-acting
bronchodilators (HR1.7; P < 0.001), inhaled (HR1.2; P = 0.005) or systemic corticosteroids (HR1.8; P = 0.015) were
significantly associated with exacerbation when having had no exacerbation at most recent visit. Higher FEV1/FVC (HR0.9;
P = 0.008) and higher FEV1 values (HR0.9; P = 0.001) were protective. When already having had an exacerbation at the
most recent visit, pronounced dyspnea (HR for mMRC grade 4 1.9; P = 0.026) and cerebrovascular insult (HR2.1; P = 0.003)
were significantly associated with re-exacerbation. Physical activity (HR0.6; P = 0.031) and treatment with long-acting
anticholinergics (HR0.7; P = 0.044) seemed to play a significant protective role. In a best subset model for exacerbation,
higher FEV1 significantly reduced and occurrence of sputum increased the probability of exacerbation. In the same model
for re-exacerbation, coronary heart disease increased and hospitalization at most recent visit seemed to reduce the risk for
re-exacerbation.
Conclusion: Our data confirmed well-established risk factors for exacerbations whilst analyzing their predictive association
with exacerbation and re-exacerbation. This study confirmed the importance of spirometry in primary care, not only for
diagnosis but also as a risk evaluation for possible future exacerbations.
Trial registration: Our study got approval by local ethical committee in 2006 (EK Nr. 170/06) and was registered
retrospectively on ClinicalTrials.gov (NCT02065921, 19th of February 2014).
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Background
Chronic obstructive pulmonary disease (COPD) is a re-
spiratory disease, characterized by irreversible airflow
limitation and one of the most deadly, prevalent, and
costly chronic diseases [1]. COPD is known to be a pro-
gressive disease affecting more than 5% of the entire
population [2, 3]. COPD is the underlying cause for sig-
nificant morbidity, it ranks 10th on a worldwide ranking
assessing disease burden by disability-adjusted life years
(DALYs) with 27.7 DALYs [4]. According to the WHO
health statistics of 2008, COPD was the fourth leading
cause of mortality in 2004 and is projected to be the
third leading cause of death in 2030 [5]. Like other
chronic diseases, COPD causes a substantial human and
economic burden to society [6]. The growing worldwide
burden is considered to be mainly due to cigarette
smoking, environmental and occupational factors and
the aging population [7, 8].
In this context, the Swiss COPD cohort was estab-
lished in 2006 to collect spirometric and other relevant
data of COPD patients treated in a primary care setting
and to facilitate research on the diagnosis, treatment and
clinical course of COPD [9–11].
Acute exacerbations of COPD (AECOPD) are key
events in COPD. Not only do exacerbations increase the
economic burden for society [12], but they are also associ-
ated with a faster decline in lung function [13, 14], lower
quality of life [15] and increased morbidity [16] and mor-
tality [17]. Although AECOPD are an emerging field of re-
search and several possible associated risk factors have
been reported, they are still not clearly defined. So far, the
greatest risk factor seems to be a previous history of exac-
erbations [18]. More recently, Make et al. introduced an
easily applicable score to predict short-term risk of COPD
exacerbations (SCOPEX) which includes the following
factors: sex, number of COPD maintenance medications,
number of exacerbations in the previous year, FEV1/FVC
ratio and reliever use [19]. Almagro et al. described the
CODEX index consisting of comorbidity assessment with
Charlson index, airflow obstruction, dyspnea and previous
severe exacerbations to predict survival and readmission
after hospitalization for AECOPD [20]. With regards to
re-exacerbation in patients with AECOPD, a recent study
found age, lung function impairment, frequency of
AECOPD during the previous year and some parameters
of current AECOPD (such as pleural effusion, use of
accessory respiratory muscles, medication and
hospitalization length) to have a strong predictive capacity
[21]. Another study showed an association between pro-
longed symptomatic duration of AECOPD and poorer
health status with the risk of developing a new event [22].
In the primary care setting, however, only sparse data
about potential risk factors for exacerbations and
re-exacerbations are currently available [23].
The aims of this study were to analyze data of the en-
tire patient population of the Swiss COPD cohort in a
descriptive way and secondly, to evaluate known risk
factors and their predictive association with exacerbation
and re-exacerbation within a multi-state model frame-
work previously reported by Therneau and Grambsch
[24, 25].
Methods
Study design and patient population
We received ethical approval for this
questionnaire-based observational COPD cohort study
by the local ethical committee in 2006 (EK Nr. 170/06)
and subsequently by ethical committees of all other par-
ticipating Swiss cantons. A generic letter was sent to 225
GPs in 23 Swiss cantons and an initial total of 139 GPs
agreed to participate. The study was also registered on
ClinicalTrials.gov (NCT02065921).
All participating patients provided written informed
consent. COPD patients treated in primary care were clin-
ically evaluated at least every six months by their GPs.
Spirometry was performed using an EasyOne™ spirometer
(n.d.d. Medizintechnik AG, Zurich, Switzerland). Initially,
all participating GPs were instructed how to perform spir-
ometry in accordance with the guidelines of the American
Thoracic Society and the European Respiratory Society
[26, 27]. The Swiss reference values by Brändli et al. were
used to calculate predicted values [28, 29]. In accordance
with GOLD-guidelines, airway obstruction was defined as
presence of a FEV1/FVC < 70% after bronchodilation. A
standardized questionnaire included spirometric parame-
ters, as well as clinical and demographic data. All partici-
pating patients provided written informed consent.
Details of patients excluded from the analysis are
shown in Fig. 1. Until the end of 2014, 1,312 patients
have been included in the study. After exclusion of 65
patients due to incomplete data, we analyzed data of a
total of 1,247 patients (=overall population). A substan-
tial amount of cohort patients with a clinical diagnosis
of COPD did either not fulfill spirometric diagnostic cri-
teria for COPD or had missing spirometric data (n =
366). After exclusion of patients who did not have at
least one follow up visit, 748 patients were available for
the model analysis (=model population).
Collected data
Patients were seen at least every six months by their
GPs. At baseline, demographic information such as
age, sex, height, weight, year of diagnosis of COPD
and risk factors (e.g. smoking status) was collected.
Patients performed post-bronchodilatator lung func-
tion testing every six months and spirometric data
(FEV1, FVC and FEV1/FVC ratio) was collected. At
every visit, patients were asked about symptoms such
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as dyspnea (assessed for all patients with mMRC dyspnea
scale), cough and sputum production. Information about
COPD medication and non-pharmacological treatments
was registered, as well as information about hospitali-
zations and exacerbations since the most recent visit.
Exacerbation was defined as worsening of clinical
symptoms leading to a change in treatment. Anon-
ymized data of all patients was captured in a central
electronic database.
Statistical analysis
Descriptive statistics were performed presenting mean
and standard deviation (SD) or count and percentage as
appropriate. In order to compare categorical data between
study groups, chi-square tests were used. In the case of
continuous data T-tests were used.
In order to predict exacerbation until the next visit
based on the knowledge of exacerbation since the most
recent visit, a multistate model on the basis of a
multi-state Cox model approach reported by Therneau
and Grambsch [25] was performed. This model was used
to describe a cohort of patients with Crohn’s disease in
Olmsted County Minnesota [24]. The argumentation for
using this model was based on some similar characteris-
tics shared by Crohn’s disease and COPD: both are (i)
chronic diseases with (ii) waxing and waning symptoms,
which (iii) make it difficult to describe or predict
long-term outcomes. Multistate models are appropriate
in case of events (or states) that occur from time point
to time point. In our case, the event is defined as “having
an exacerbation since the most recent visit”. The follow-
ing four state changes from visit to visit are possible:
exacerbation to no exacerbation, exacerbation to exacer-
bation, no exacerbation to exacerbation, no exacerbation
to no exacerbation.
Further details and examples are described in a book
by Therneau and Grambsch [25].
For each state change potential predictors can be
identified. Results are presented as hazard ratios (HR)
with 95% confidence intervals for each predictor sep-
arately. Additionally, a multivariable best subset of
predictors was selected using Akaike’s information cri-
terion (AIC) [30]. No multivariable model including
all available predictors was done, because the esti-
mated HRs and p are often misleading and could be
misinterpreted.
Results are expressed as HRs with corresponding 95%
confidence intervals and p. For ordinal and continuous
variables HRs were generally expressed increasing the
predictor one unit. For age, FEV1, FVC, FEV1/FVC ratio
and BMI, HRs were expressed increasing the predictor
ten units.
A p < 0.05 was considered to indicate statistical signifi-
cance. This study was exploratory, therefore p were not
adjusted for multiple comparisons.
All evaluations were done using the statistical software
R (R Core Team, 2015, R: a language and environment




Baseline characteristics of the overall and model popula-
tion are summarized in Table 1. The majority in both
populations were males. Fifty-three percent were
ex-smokers and 47% current smokers. Mean follow up
time of our overall population was 1.2 years (±0.8 years)
and mean follow up time of the model population was
1.39 years (±0.68 years).
With regard to lung function, mean FEV1/FVC-ratio
was 59% for the overall and 53.1% for the model popula-
tion. In both the overall and the model population,
patients with GOLD 1 severity of airflow limitation were
rather scarcely represented with 3.63 and 4.46%
Fig. 1 Study population
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Table 1 Baseline characteristics of the overall and model population
Overall population Known Model population Known
General characteristics N (%)/Mean (±SD) N (%) N (%)/Mean (±SD) N (%)
N total 1247 748
Age (years) 66.4 (±11.8) 1243 (99.7%) 67.3 (±11.6), 748 (100%)
Sex, males 752 (60.4%) 1245 (99.8%) 471 (63.0%) 748 (100%)
BMI (kg/m2) 26.5 (±5.5) 1129 (90.5%) 26.2 (±5.29) 696 (93.0%)
Current smokers 577 (46.6%) 1239 (99.4%) 328 (44.1%) 744 (99.5%)
Ex-smokers 662 (53.4%) 1239 (99.4%) 416 (55.9%) 744 (99.5%)
Lung function
FEV1/FVC 59.0% (±15.6) 1149 (92.1%) 53.1% (±11.5) 748 (100%)
FEV1 %Ref 54.9% (±20.8) 1088 (87.2%) 49.5% (±17.4) 718 (96.0%)
FVC %Ref 69.6% (±19.3) 1099 (88.1%) 69.5% (±18.9) 718 (96.0%)
No COPD 268 (24.3%) 1101 (88.3%) 0 (0%) 718 (96.0%)
GOLD 1 40 (3.63%) 1101 (88.3%) 32 (4.46%) 718 (96.0%)
GOLD 2 351 (31.9%) 1101 (88.3%) 303 (42.2%) 718 (96.0%)
GOLD 3 323 (29.3%) 1101 (88.3%) 287 (40.0%) 718 (96.0%)
GOLD 4 119 (10.8%) 1101 (88.3%) 96 (13.4%) 718 (96.0%)
Symptoms
mMRC dyspnea scale 0–1 610 (50.8%) 1201 (96.3%) 355 (49.0%) 725 (96.9%)
mMRC dyspnea scale 2 350 (29.1%) 1201 (96.3%) 219 (30.2%) 725 (96.9%)
mMRC dyspnea scale 3 199 (16.6%) 1201 (96.3%) 129 (17.8%) 725 (96.9%)
mMRC dyspnea scale 4 42 (3.50%) 1201 (96.3%) 22 (3.03%) 725 (96.9%)
Cough 864 (69.4%) 1245 (99.8%) 515 (68.9%) 747 (99.9%)
Sputum 731 (58.8%) 1243 (99.7%) 446 (59.7%) 747 (99.9%)
Pharmacological COPD treatment
Short-acting bronchodilators 466 (37.5%) 1242 (99.6%) 294 (39.4%) 747 (99.9%)
Long-acting ß2-agonists (LABA) 355 (28.7%) 1237 (99.2%) 235 (31.5%) 745 (99.6%)
Long-acting muscarinic antagonists (LAMA) 509 (41.1%) 1238 (99.3%) 345 (46.2%) 746 (99.7%)
Inhaled corticosteroids (ICS) 270 (21.8%) 1237 (99.2%) 178 (23.8%) 747 (99.9%)
Inhaled combination therapy (LABA+ICS) 632 (50.9%) 1242 (99.6%) 390 (52.1%) 748 (100%)
Systemic corticosteroids 73 (5.89%) 1240 (99.4%) 42 (5.61%) 748 (100%)
Comorbidities
Asthma 221 (20.6%) 1073 (86.0%) 130 (19.9%) 654 (87.4%)
Diabetes mellitus 141 (13.1%) 1074 (86.1%) 86 (13.1%) 655 (87.6%)
Hypertension 601 (55.8%) 1078 (86.4%) 366 (55.9%) 655 (87.6%)
Coronary heart disease 228 (21.2%) 1075 (86.2%) 148 (22.6%) 655 (87.6%)
Heart failure 159 (14.8%) 1073 (86.0%) 96 (14.7%) 654 (87.4%)
Cancer (other than lung cancer) 52 (4.85%) 1072 (86.0%) 36 (5.51%) 653 (87.3%)
Lung cancer 29 (2.70%) 1073 (86.0%) 16 (2.45%) 654 (87.4%)
Cerebrovascular Insult (CVI) 36 (3.36%) 1073 (86.0%) 24 (3.67%) 654 (87.4%)
Physical activity
Sports (at least twice a week) 334 (28.2%) 1183 (94.9%) 200 (27.6%) 724 (96.8%)
Pulmonary rehabilitation 86 (7.01%) 1226 (98.3%) 55 (7.40%) 743 (99.3%)
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respectively. Most patients had GOLD 2 or 3 severity of
airflow limitation.
Regarding dyspnea, 50.8% of the overall and 49.0% of
the model population had few symptoms with an mMRC
grade 0–1. Five hundred and ninety-one patients (49.2%)
of the overall population and 370 patients (51.0%) of the
model population had more symptoms with an mMRC
grade 2 or higher. The majority of all patients com-
plained of cough and sputum.
Short acting bronchodilators were prescribed in less
than half of our cohort’s patients. Concerning
long-acting inhaled medication (ß2-agonists or anticho-
linergics), inhaled combination therapy (long-acting
ß2-agonists (LABA) and inhaled corticosteroids) and
long-acting muscarinic antagonists (LAMA) were pre-
scribed most commonly. Systemic steroids were rarely
used (see Table 1). Inhaled corticosteroids only (without
LABA or LAMA) were used in a very small minority (26
out of 1,072 patients (2.1%)).
Frequent comorbidities were high blood pressure
in more than half, as well as coronary heart disease
and asthma in a fifth of all patients. Other frequently
detected comorbidities were diabetes mellitus and
heart failure.
Factors associated with exacerbation and re-exacerbation
Results of the univariate analysis to assess factors associ-
ated with the risk “having an exacerbation until next
visit” and “having a re-exacerbation until next visit” are
shown in Table 2 and are based on a multistate model
described above.
When having had no exacerbation at the most recent
visit, lower FEV1/FVC and FEV1 values showed a signifi-
cant association with exacerbation as well as
hospitalization for any reason and pronounced dyspnea
at the most recent visit. Furthermore, prescription of
short-acting bronchodilators, inhaled or systemic cortico-
steroids were significantly associated with exacerbation.
When already having had an exacerbation at the most
recent visit, pronounced dyspnea and cerebrovascular
insult were significantly associated with re-exacerbation.
Physical activity and treatment with LAMAs seemed to
play a significant protective role.
Best subset model
Table 3 shows the best subset models for predictive
factors associated with exacerbation and re-exacerbation
based on Akaike’s information criterion (AIC) [30]. We
selected the following factors to design a best subset
model: age, gender, BMI, current smoking history, FEV1
and FVC in percentage of reference values, respiratory
symptoms (sputum, cough and dyspnea measured by
mMRC dyspnea scale), hospitalization for any reason
and main comorbidities (asthma, coronary heart disease,
heart failure, hypertension and diabetes mellitus).
Higher FEV1 values significantly reduced the probabil-
ity of exacerbation when not having had an exacerbation
at the most recent visit, whereas sputum increased prob-
ability of experiencing an exacerbation until next visit.
The best subset model for re-exacerbation included pre-
vious hospitalization and coronary heart disease. While
coronary heart disease increased risk of re-exacerbation
significantly, hospitalization at the most recent visit
seemed to reduce risk for re-exacerbation in the best sub-
set model.
Discussion
With this multicenter, prospective, primary care cohort
study, we were able to characterize a primary care
COPD population and we were able to assess risk factors
associated with exacerbation and re-exacerbation. In
particular, lung function parameters (lower FEV1/FVC
and lower FEV1) and symptoms such as pronounced
dyspnea (in particular mMRC grade 4) or sputum pro-
duction showed a significant association with exacerba-
tion in a univariate analysis, whereas of these factors
only pronounced dyspnea was significantly associated
with re-exacerbation. Furthermore, prescription of
short-acting bronchodilators, inhaled or systemic corti-
costeroids was significantly associated with exacerbation.
We considered short-acting bronchodilator and cortico-
steroid prescription in this context most likely as surro-
gate markers of disease or symptom severity.
Using a multivariate Cox-regression model, formerly
described in patients with Crohn’s disease, we were able to
generate best subset models consisting of only two factors
[24, 25]. Taking FEV1-values and sputum into account,
seemed to be most relevant in this primary care setting,
when assessing the transition from having no exacerbation
to having an exacerbation. These findings underline the
importance of regular symptom and spirometric assess-
ment in primary care even in so-called “stable disease”.
Finally, re-exacerbation was significantly associated
with pronounced dyspnea and patients having had a
cerebrovascular insult or being less physically active.
These results could partly support a benefit from
pulmonary and physical rehabilitation. On the other
hand, treatment with long-acting anticholinergics
seemed to play a significant protective role, which seems
reasonable. The best subset model for re-exacerbation
included only previous hospitalization for any reason
and coronary heart disease. Whilst coronary heart
disease increased risk of re-exacerbation significantly,
hospitalization at last visit seemed to reduce risk for
re-exacerbation in the best subset model. An explanation
for these findings could be that patients with comorbidi-
ties are more likely to experience frequent exacerbations
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[31] and that these patients might possibly benefit
from in-patient treatment to stabilize their condition.
However, it is still counterintuitive to some extent
that overall hospitalization is on the other hand
strongly associated with exacerbation in the univariate
analysis.
Baseline characteristics of our cohort were similar in
comparison with Norwegian, Swedish, Canadian and UK
primary care cohorts [32–35]. However, with regards to
GOLD severity grades, our patient population seemed to
have more severe disease compared to the cohorts
described by Wurst and colleagues (UK) or Sundh and
colleagues (Sweden) [32, 34]. In accordance with the
findings of Green et al. our analysis confirms the high
prevalence of comorbidities, in contrast to their findings
we found even higher rates of cardiac comorbidities [33].
Table 2 Factors associated with exacerbation and re-exacerbation, univariate analysis
Factors associated with exacerbation Factors associated with re-exacerbation
General characteristics HR Lower/upper 95% confidence
interval
p HR Lower/upper 95% confidence
interval
p
Age (years) 1.084 0.977/1.203 0.127 1.168 0.977/1.396 0.088
Male sex 0.825 0.654/1.042 0.107 0.991 0.705/1.393 0.958
BMI (kg/m2) 0.832 0.650/1.064 0.142 1.201 0.847/1.703 0.304
Current smokers 0.954 0.755/1.205 0.693 0.803 0.574/1.122 0.198
Lung function
FEV1/FVC 0.862 0.773/0.962 0.008 0.953 0.810/1.121 0.559
FEV1 %Ref 0.877 0.812/0.947 0.001 1.000 0.864/1.157 0.997
FVC %Ref 0.941 0.868/1.019 0.132 0.998 0.896/1.111 0.966
Symptoms
mMRC dyspnea scale 0–1 Reference Reference
mMRC dyspnea scale 2 1.349 1.055/1.726 0.017 1.332 0.859/2.065 0.200
mMRC dyspnea scale 3 1.371 0.993/1.892 0.055 1.434 0.925/2.223 0.107
mMRC dyspnea scale 4 3.036 1.930/4.777 <
0.001
1.974 1.083/3.600 0.026
Cough 1.238 0.998/1.535 0.052 1.344 0.838/2.156 0.220
Sputum 1.396 1.126/1.731 0.002 1.160 0.765/1.759 0.485
Treatment
Short-acting bronchodilators 1.665 1.323/2.096 <
0.001
1.072 0.774/1.485 0.677
Long-acting ß2-agonists (LABA) 1.037 0.813/1.324 0.768 0.857 0.612/1.199 0.368
Long-acting muscarinic antagonists
(LAMA)
0.918 0.739/1.141 0.440 0.723 0.527/0.991 0.044
Inhaled corticosteroids (ICS) 1.460 1.120/1.903 0.005 0.965 0.694/1.343 0.834
Inhaled combination therapy (LABA+ICS) 1.200 0.956/1.505 0.116 1.397 0.988/1.974 0.058
Systemic corticosteroids 1.764 1.118/2.785 0.015 0.820 0.544/1.235 0.342
Comorbidities
Asthma 1.271 0.965/1.675 0.088 0.997 0.676/1.472 0.988
Diabetes mellitus 1.122 0.836/1.507 0.433 1.185 0.782/1.796 0.424
Hypertension 1.108 0.869/1.413 0.408 0.852 0.610/1.190 0.348
Coronary heart disease 1.239 0.933/1.644 0.139 1.177 0.796/1.741 0.413
Heart failure 0.988 0.695/1.404 0.947 0.988 0.598/1.631 0.961
Cerebrovascular Insult (CVI) 0.975 0.509/1.868 0.940 2.073 1.288/3.337 0.003
Other
Sports (at least twice a week) 1.062 0.830/1.360 0.630 0.609 0.388/0.956 0.031
Pulmonary rehabilitation 1.061 0.636/1.769 0.821 0.578 0.294/1.135 0.111
Hospitalization for any reason 1.701 1.021/2.833 0.041 0.939 0.593/1.487 0.788
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The risk factors associated with exacerbation and
re-exacerbation are largely in accordance with the litera-
ture [18, 36, 37], however the association of prescription
of short-acting bronchodilators, inhaled or systemic cor-
ticosteroids was perhaps surprising, as some large trials
have shown significant decrease in exacerbation risk
with the use of inhaled steroids [38, 39]. However, a
recent study of Magnussen et al. showed a similar risk of
moderate or severe exacerbations for patients discon-
tinuing inhaled glucocorticoids compared to patients
who continued inhaled glucocorticoid treatment [40]. In
addition, similar findings have been described in the Ber-
gen COPD Cohort Study, a study which was designed to
assess the ability of COPD characteristics and systemic
inflammatory markers to predict the risk for acute
COPD exacerbation frequency and duration [41]. Taking
this into account, we suppose, as mentioned above, the
prescription of these drugs to be surrogate markers for
disease or symptom severity.
Concerning the prediction of exacerbation or hospital
readmissions, some studies showed the value of other
factors such as short acting bronchodilator use [42] or
four meter gait speed, which we did not assess for in our
cohort [43]. Furthermore, various new predictive scores
such as the CODEX Index, the SCOPEX and the re-AE
INDEX were established, which could be useful also in a
primary care setting [19–21]. Unfortunately we were not
able to test the SCOPEX, which seems to be easily ap-
plicable in primary care, as we have not recorded daily
reliever use in our study population so far. Some recent
research underlined the value of clinical symptoms and
questioned the sensitivity of airflow limitation to diag-
nose smoking induced disease [44, 45]. Even though our
best subset model for exacerbation highlights the im-
portance of FEV1, which furthermore is in accordance
with recently analyzed large data sources [46], we do
agree that clinical symptoms do not only determine the
degree of suffering of the patient but are a valuable and
easy tool to evaluate the course of disease in primary
care. The number of patients included in our cohort
who did not fulfill a spirometric COPD diagnosis high-
lights the existence of patients with important clinical
burden not fulfilling formal diagnostic criteria.
Limitations and strengths of this study
This study has some limitations. Firstly, for reasons of
anonymity, patient information was captured with ques-
tionnaires filled out by treating physicians. Therefore, it
was not possible to gather further information by retro-
spective chart review, which would have been useful for
the generation of a possibly more accurate exacerbation
model. Secondly, as GPs participated on a voluntary
basis and were not chosen in a randomized way, a cer-
tain overrepresentation of GPs interested in respiratory
medicine might exist. However, given the similarity to
other study populations, we believe that our patient
sample is representative of the primary care setting.
Thirdly, our cohort included few patients with GOLD 1
stage of disease and the mean follow up period was quite
short.
However, we believe that this study has considerable
strengths. The prospective, multicenter design including
different GPs from various regions in Switzerland en-
sures representative, observational data from a primary
care setting. Compared to other studies including pa-
tients with admission for AECOPD [20, 21] or excluding
patients with asthma [19] our study population seems
closer to a real life miscellaneous primary care popula-
tion with a priori “stable” disease. Since we only in-
cluded data from patients with a spirometric diagnosis
of COPD for univariate and multivariate analysis, our
findings should be accurate and to some extent
generalizable in a primary care setting. Although the
chosen model for multivariate analysis seems to have
been used for the first time in COPD, which could be a
limitation, it allows for relevant analysis and seems to be
adequate for the present data structure and patient
population.
Implications of this study
Our data confirmed the existence of a non-negligible
number of patients with a clinical diagnosis of COPD
not fulfilling spirometric criteria and we think that these
patients are not covered enough by current guidelines.
We therefore see a need for further research and a
greater academic awareness concerning diagnostic pro-
cedures and symptom relief in patients suffering from
chronic respiratory symptoms with normal spirometry
and patients suffering from multifactorial dyspnea.
Clearly simple diagnostic tools to better characterize and
ultimately improve treatment for patients with respira-
tory symptoms in primary care are needed. Some re-
cently described predictive scores might help physicians
in daily practice. Furthermore, we believe in the useful-
ness of a multistate model approach to better describe
and ultimately improve prediction of course of disease
in patients suffering from COPD, which would not only
help doctors but health policy makers as well. “Big data”
Table 3 Best subset models, multivariate Cox-regression
Factors HR SE p
Best exacerbation subset model
FEV1 %Ref 0.889 0.0414 0.0046
Sputum 1.439 0.1492 0.0150
Best re-exacerbation subset model
Coronary heart disease 1.567 0.226 0.047
Hospitalization for any reason 0.583 0.306 0.078
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and new innovative ways to generate personalized health
care data could be helpful to better characterize different
phenotypes and personalize treatment accordingly.
Meanwhile, we firmly believe in the utility of primary
care based cohort studies in making real life data of our
patients available for systematic evaluation.
Conclusions
Our study confirmed well-established risk factors for
AECOPD and confirmed the importance of spirometry
in primary care, not only for the diagnosis of COPD in
accordance with current guidelines but also as an im-
portant tool in order to improve treatment and reduce
the risk for future exacerbations. Therefore, spirometry
together with clinical assessment and medical history
taking should build the basis for evaluating COPD pa-
tients in primary care. However, there is an ongoing de-
bate on the sensitivity of spirometry as a diagnostic tool
and our data revealed a substantial number of primary
care patients suffering from respiratory symptoms whilst
not fulfilling diagnostic spirometric criteria for COPD.
Treatment for this patient collective remains challenging
to physicians in their daily life and treatment guidelines
probably do not reflect these circumstances adequately
yet. Even if it is fairly difficult to perform trials in a pri-
mary care setting, we believe that further research is
needed and more specifically elaborated treatment
guidelines taking the circumstances of primary care into
account.
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